Platelets and Atherothrombosis: An Essential Role for Inflammation in Vascular Disease — A Review
暂无分享,去创建一个
Á. Avezum | S. Steinhubl | M. Sabatine | M. Endres | L. Newby | M. Connor | S. Uchiyama | E. Wahlberg
[1] J. Farmer. Reversal of atherosclerosis with aggressive lipid lowering. , 2005, Current atherosclerosis reports.
[2] E. Tuzcu,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease , 2005 .
[3] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[4] S. Devaraj,et al. C-Reactive Protein: Risk Marker or Mediator in Atherothrombosis? , 2004, Hypertension.
[5] D. Newby,et al. Upregulation of the CD40/CD40 Ligand Dyad and Platelet-Monocyte Aggregation in Cigarette Smokers , 2004, Circulation.
[6] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[7] G. Cagney,et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. , 2004, Blood.
[8] P. Burger,et al. Platelets in Inflammation and Thrombosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[9] J. Kaski,et al. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. , 2003, Journal of the American College of Cardiology.
[10] E. Topol,et al. Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.
[11] H. Bae,et al. Serial Measurement of Surface Expressions of CD63, P-Selectin and CD40 Ligand on Platelets in Atherosclerotic Ischemic Stroke , 2003, Cerebrovascular Diseases.
[12] W. Koenig,et al. Utility of inflammatory markers in the management of coronary artery disease. , 2003, The American journal of cardiology.
[13] M. Hori,et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. , 2003, Atherosclerosis.
[14] K. Newby,et al. C‐Reactive Protein: A Novel Marker of Cardiovascular Risk , 2003, Cardiology in review.
[15] Petr Jarolim,et al. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones , 2003, Circulation.
[16] Gary L Myers,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[17] M. Gawaz,et al. Engagement of Glycoprotein IIb/IIIa (&agr;IIb&bgr;3) on Platelets Upregulates CD40L and Triggers CD40L-Dependent Matrix Degradation by Endothelial Cells , 2002, Circulation.
[18] Patrick André,et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.
[19] F. Cambien,et al. Interleukin-18 Is a Strong Predictor of Cardiovascular Death in Stable and Unstable Angina , 2002, Circulation.
[20] A. Connor,et al. The way I see it: House officers need formal career development , 2002 .
[21] A. Mattioli,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[22] L. Drouet. Atherothrombosis as a Systemic Disease , 2002, Cerebrovascular Diseases.
[23] Catherine Sudlow,et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.
[24] P. Libby,et al. CD40 Signaling and Plaque Instability , 2001, Circulation research.
[25] P. Ridker,et al. Novel clinical markers of vascular wall inflammation. , 2001, Circulation research.
[26] Deepak L. Bhatt,et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. , 2001, The American journal of cardiology.
[27] Paul M. Ridker,et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.
[28] P. Mcgeer,et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.
[29] P. Ridker,et al. Soluble P-Selectin and the Risk of Future Cardiovascular Events , 2001, Circulation.
[30] K. Schrör,et al. Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel , 2001, Platelets.
[31] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.
[32] M. Daemen,et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[33] P. Libby,et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Banchereau,et al. CD40‐CD40 ligand , 2000, Journal of leukocyte biology.
[35] P. Ridker,et al. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. , 1999, The American journal of cardiology.
[36] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[37] P. Ridker,et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.
[38] J. Finkelstein,et al. Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. , 1998, The American journal of pathology.
[39] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[40] Reinhold Förster,et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.
[41] R. D'Agostino,et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.
[42] C. Visser,et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. , 1997, Circulation.
[43] V. Fuster,et al. Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.
[44] A. Aruffo,et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. , 1993, Science.
[45] G. Lozanski,et al. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. , 1992, Cytokine.
[46] D. Symmons,et al. Cause of death in rheumatoid arthritis. , 1984, British journal of rheumatology.
[47] Eric J. Topol,et al. Scientific and therapeutic advances in antiplatelet therapy , 2003, Nature Reviews Drug Discovery.
[48] Harry,et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.